钠-葡萄糖协同转运蛋白2抑制剂在腹膜透析中的研究及应用前景
Sodium-glucose co-transporter 2 inhibitors in peritoneal dialysis patients
余乐 1成水芹 1俞雨生1
作者信息
- 1. 东部战区总医院 国家肾脏疾病临床医学研究中心(南京,210016)
- 折叠
摘要
钠-葡萄糖协同转运蛋白 2 抑制剂(SGLT2i)作为一种新型口服降糖药,对 2 型糖尿病或非糖尿病患者都表现出良好的心肾保护作用,并可改善慢性肾脏病患者的心肾结局.虽然目前临床试验已将纳入人群的估算肾小球滤过率(eGFR)扩展至更低水平,但仍排除了eGFR＜20 mL/(min·1.73 m2)的患者,SGLT2i的心肾保护作用能否延续至维持性透析期是临床关注的重点.此外,SGLT2i的抗炎和抗纤维化作用可能对腹膜透析(PD)患者维持腹膜功能有益.因此,SGLT2i在PD患者中的应用值得进一步探索.
Abstract
Sodium-glucose co-transporter 2 inhibitors(SGLT2i),a novel type of oral antihyperglycaemic drugs,have demonstrated favorable cardiorenal protective effects in patients with type 2 diabetes or non-diabetic individuals.They can also improve cardiorenal outcomes in patients with chronic kidney disease.Although clinical trials have expanded the inclusion criteria for estimated glomerular filtration rate(eGFR)to lower levels,patients with eGFR＜20 ml/min/1.73m＾2 are still excluded.Whether the continuation of cardiorenal protective effects of SGLT2i during the maintenance dialysis phase is an area of clinical focus.Additionally,the anti-inflammatory and anti-fibrotic properties of SGLT2i may benefit the preservation of peritoneal function in patients undergoing peritoneal dialysis(PD).Therefore,further exploration of the application of SGLT2i in PD patients is warranted.
关键词
钠-葡萄糖协同转运蛋白2抑制剂/腹膜透析/心肾保护/残余肾功能/腹膜Key words
sodium-glucose co-transporter 2 inhibitors/peritoneal dialysis/cardiorenal protection/residual kidney function/peritoneal membrane引用本文复制引用
基金项目
国家自然科学基金面上项目(82370733)
出版年
2024
NETL
NSTL
万方数据